Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353891 | 1.00 | SRC (0.45) | SRCPARP1DHFRKMT2APDPK1 | |
| SCHEMBL30353903 | 0.86 | SRC (0.48) | SRCPARP1DHFRKMT2APDPK1 | |
| SCHEMBL6912846 | 0.86 | SRC (0.48) | SRCPARP1DHFRKMT2APDPK1 | |
| SCHEMBL6912439 | 0.82 | SRC (0.45) | SRCPARP1DHFRKMT2APDPK1 | |
| SCHEMBL15680657 | 0.79 | SRC (0.42) | SRCPARP1DHFRKMT2APDPK1 | |
| SCHEMBL15710544 | 0.79 | PARP1 (0.44) | SRCPARP1KMT2APDPK1EGFR | |
| SCHEMBL21808021 | 0.79 | PARP1 (0.51) | SRCPARP1DHFRKMT2APDPK1 | |
| SCHEMBL30353912 | 0.79 | PARP1 (0.44) | SRCPARP1KMT2APDPK1EGFR | |
| SCHEMBL1468319 | 0.78 | TNF (0.46) | SRCPARP1DHFRKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL28100847 | 0.78 | PARP1 (0.43) | SRCPARP1KMT2APDPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110573505-B | C 5 -anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-3615522-B1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2020-11-10 | — | — | US | disclosed |
| EP-3615522-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca (SE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573505-A | C5-anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20190263787-A1 | C5-anilinoquinazoline Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-08-29 | — | — | US | disclosed |
| US-10273227-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-04-30 | — | — | US | disclosed |
| WO-2018197642-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | WO | disclosed |
| US-20180312490-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263787-A1 | C5-anilinoquinazoline Compounds and Their Use in Treating Cancer | KIT, C5, C9 | SRC 2261/4885PARP1 158/4885DHFR 2430/4885 |
| US-20180312490-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | KIT, C5, C9 | SRC 2261/4885PARP1 158/4885DHFR 2430/4885 |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | KIT, C5, C9 | SRC 2261/4885PARP1 158/4885DHFR 2430/4885 |
| US-10273227-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | KIT, C5, C9 | SRC 2261/4885PARP1 158/4885DHFR 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.